Aldeyra Therapeutics Inc expected to post a loss of 11 cents a share - Earnings Preview

Aldeyra Therapeutics

30/04/2024 19:19

* Aldeyra Therapeutics Inc  ALDX.OQ   ALDX.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 2
(estimated) for the period ending January 1 0001
    * The Lexington Massachusetts-based  company is expected to
report
revenue of $2 million, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Aldeyra Therapeutics Inc
is
for a loss of 11 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aldeyra
Therapeutics Inc is $10.00​, above​ its last closing price
of $4.05. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.05       -0.14      -0.08     Beat    43
 Sep. 30 2023  -0.22       -0.24      -0.14     Beat    41.3
 Jun. 30 2023  -0.31       -0.31      -0.15     Beat    51.8​
 Mar. 31 2023  -0.29       -0.29      -0.27     Beat    7.4
 ​​Jan.        -0.29       -0.31      -0.22     Beat    29.7
 1 0001                                                 
 Sep. 30 2022  -0.33       -0.34      -0.25     Beat    27.3​
 Jan. 1 0001   -0.32       -0.31      -0.30     Beat    3.5
 Mar. 31 2022  -0.32       -0.32      -0.29     Beat    8
 This summary was machine generated April 30 at 18:19 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)